CA3031419C - N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors - Google Patents
N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors Download PDFInfo
- Publication number
- CA3031419C CA3031419C CA3031419A CA3031419A CA3031419C CA 3031419 C CA3031419 C CA 3031419C CA 3031419 A CA3031419 A CA 3031419A CA 3031419 A CA3031419 A CA 3031419A CA 3031419 C CA3031419 C CA 3031419C
- Authority
- CA
- Canada
- Prior art keywords
- group
- compound
- alkyl
- cancer
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371504P | 2016-08-05 | 2016-08-05 | |
| US62/371,504 | 2016-08-05 | ||
| US201762454101P | 2017-02-03 | 2017-02-03 | |
| US62/454,101 | 2017-02-03 | ||
| PCT/US2017/045428 WO2018027097A1 (en) | 2016-08-05 | 2017-08-04 | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3031419A1 CA3031419A1 (en) | 2018-02-08 |
| CA3031419C true CA3031419C (en) | 2021-08-24 |
Family
ID=59677319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3031419A Active CA3031419C (en) | 2016-08-05 | 2017-08-04 | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10829488B2 (enExample) |
| EP (3) | EP3569601B1 (enExample) |
| JP (2) | JP6651180B2 (enExample) |
| KR (2) | KR102376764B1 (enExample) |
| CN (2) | CN109311871B (enExample) |
| AU (2) | AU2017305508B2 (enExample) |
| CA (1) | CA3031419C (enExample) |
| CY (1) | CY1123859T1 (enExample) |
| DK (1) | DK3494115T3 (enExample) |
| ES (1) | ES2849959T3 (enExample) |
| HR (1) | HRP20202073T1 (enExample) |
| HU (1) | HUE053414T2 (enExample) |
| IL (2) | IL264059B (enExample) |
| LT (1) | LT3494115T (enExample) |
| MX (2) | MX381588B (enExample) |
| MY (1) | MY199409A (enExample) |
| PE (1) | PE20190711A1 (enExample) |
| PH (1) | PH12019500231A1 (enExample) |
| PT (1) | PT3494115T (enExample) |
| RS (1) | RS61821B1 (enExample) |
| RU (2) | RU2744358C2 (enExample) |
| SA (1) | SA519401020B1 (enExample) |
| SG (2) | SG10201913643YA (enExample) |
| SI (1) | SI3494115T1 (enExample) |
| SM (1) | SMT202100025T1 (enExample) |
| WO (1) | WO2018027097A1 (enExample) |
| ZA (2) | ZA201900240B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017156398A1 (en) * | 2016-03-10 | 2017-09-14 | Assia Chemical Industries Ltd. | Solid state forms of venetoclax and processes for preparation of venetoclax |
| JP6651180B2 (ja) * | 2016-08-05 | 2020-02-19 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ | Ｂｃｌ−２阻害剤としてのｎ−（フェニルスルホニル）ベンズアミドおよび関連化合物 |
| US11053239B2 (en) | 2017-01-07 | 2021-07-06 | Fochon Pharmaceuticals, Ltd. | Compounds as BLC-2-selective apoptosis-inducing agents |
| AU2018255621B2 (en) | 2017-04-18 | 2022-03-10 | Fochon Pharmaceuticals, Ltd. | Apoptosis-inducing agents |
| JP2021521138A (ja) | 2018-04-29 | 2021-08-26 | ベイジーン リミテッド | Ｂｃｌ−２阻害剤 |
| KR20200139139A (ko) | 2018-07-31 | 2020-12-11 | 어센테지 파마 (쑤저우) 컴퍼니 리미티드 | 리툭시맙 및/또는 벤다무스틴과 병용된 Bcl-2 억제제 또는 CHOP와 병용된 Bcl-2 억제제의 시너지적 항종양 효과 |
| TWI725488B (zh) * | 2018-07-31 | 2021-04-21 | 大陸商蘇州亞盛藥業有限公司 | Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途 |
| CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| US11478469B2 (en) | 2018-07-31 | 2022-10-25 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| AU2019385458A1 (en) * | 2018-11-23 | 2021-01-07 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition and use thereof |
| TWI770503B (zh) * | 2019-05-13 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物 |
| TW202114692A (zh) * | 2019-07-02 | 2021-04-16 | 大陸商蘇州亞盛藥業有限公司 | 一種含有mTOR抑制劑的藥物組合及其應用 |
| JP2021535129A (ja) * | 2019-07-31 | 2021-12-16 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害剤及び化学療法剤の組み合わせ製品、並びに疾患の予防及び／又は治療におけるその使用 |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| TWI885019B (zh) | 2019-11-27 | 2025-06-01 | 大陸商蘇州亞盛藥業有限公司 | 用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物 |
| US12343352B2 (en) | 2019-12-03 | 2025-07-01 | Ascentage Pharma (Suzhou) Co., Ltd. | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors |
| US12514863B2 (en) | 2019-12-04 | 2026-01-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical combination and use thereof |
| WO2021113497A1 (en) | 2019-12-06 | 2021-06-10 | Loxo Oncology, Inc. | Dosing of a bruton's tyrosine kinase inhibitor |
| CN113354636B (zh) * | 2020-03-06 | 2022-08-09 | 苏州亚盛药业有限公司 | N-(苯基磺酰基)苯甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式 |
| WO2021180040A1 (zh) * | 2020-03-12 | 2021-09-16 | 南京明德新药研发有限公司 | 苯并五元环类化合物 |
| BR112022019525A2 (pt) | 2020-04-15 | 2023-11-14 | Beigene Ltd | Composto, composição farmacêutica e método para tratar doenças apoptóticas desreguladas |
| WO2021227763A1 (en) * | 2020-05-14 | 2021-11-18 | Ascentage Pharma (Suzhou) Co., Ltd. | Hplc analysis method for n- (phenylsulfonyl) benzamide compound |
| WO2022002178A1 (en) * | 2020-07-01 | 2022-01-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods for synthesizing n-(phenylsulfonyl)benzamide compounds and intermediates thereof |
| CN111537654B (zh) * | 2020-07-07 | 2020-11-10 | 上海亚盛医药科技有限公司 | N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法 |
| US20230250077A1 (en) * | 2020-07-10 | 2023-08-10 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Sulfonylbenzamide derivative and conjugate thereof, preparation method therefor and use thereof |
| CN114057728A (zh) * | 2020-08-06 | 2022-02-18 | 北京诺诚健华医药科技有限公司 | 作为bcl-2抑制剂的杂环化合物 |
| CN114073703B (zh) * | 2020-08-21 | 2022-12-30 | 苏州亚盛药业有限公司 | 用于治疗非酒精性脂肪肝炎的组合物和方法 |
| JP2023539114A (ja) * | 2020-08-21 | 2023-09-13 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | 全身性エリテマトーデスを治療する組成物及び方法 |
| WO2022111558A1 (en) * | 2020-11-25 | 2022-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | Solid dispersion, pharmaceutical preparations, preparation method, and application thereof |
| US20240316069A1 (en) * | 2020-12-28 | 2024-09-26 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods of treating multiple sclerosis |
| EP4298098A4 (en) * | 2021-02-01 | 2025-06-25 | Ascentage Pharma (Suzhou) Co., Ltd. | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS |
| EP4319800A1 (en) | 2021-04-07 | 2024-02-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
| US20250099440A1 (en) | 2021-08-02 | 2025-03-27 | Ascentage Pharma (Suzhou) Co., Ltd. | A pharmaceutical combination and use thereof |
| JP7765790B2 (ja) * | 2021-12-06 | 2025-11-07 | 杭州和正医薬有限公司 | 抗アポトーシスタンパク質ｂｃｌ－２阻害剤、医薬組成物及びその使用 |
| CN115260191B (zh) * | 2022-09-29 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌啶类化合物及其制备方法和应用 |
| EP4421075A1 (en) * | 2023-02-27 | 2024-08-28 | KRKA, d.d., Novo mesto | Process for the preparation of venetoclax and intermediates used therein |
| WO2024184233A1 (en) | 2023-03-03 | 2024-09-12 | Ionctura Sa | Combination of roginolisib and bcl-2 inhibitor in the treatment of haematological malignancy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1021343A (en) | 1912-01-17 | 1912-03-26 | M A N Mfg Company | Locking-clamp. |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US7767684B2 (en) * | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| US7842681B2 (en) | 2006-09-05 | 2010-11-30 | Abbott Laboratories | Treatment of myeoproliferative diseases |
| RU2009125575A (ru) | 2006-12-04 | 2011-01-20 | Эбботт Лэборетриз (Us) | Комплексные диагностические анализы для терапии рака |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| CN106008322B (zh) | 2008-12-05 | 2018-09-04 | Abbvie 公司 | 作为用于治疗癌症和免疫疾病的bcl-2-选择性诱发细胞凋亡药剂的磺酰胺衍生物 |
| BRPI1006115A8 (pt) | 2009-01-19 | 2017-09-26 | Abbott Lab | "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes". |
| US9045800B2 (en) | 2009-02-11 | 2015-06-02 | Abbvie Inc. | Methods and compositions for identifying, classifying and monitoring subject having Bcl-2 family inhibitor-resistant tumors and cancers |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN102448959B (zh) * | 2009-05-26 | 2015-06-17 | 艾伯维巴哈马有限公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| TWI520960B (zh) * | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| MX349533B (es) | 2010-10-29 | 2017-08-02 | Abbvie Inc | Dispersiones solidas que contienen un agente inductor de apoptosis. |
| AR083946A1 (es) * | 2010-11-23 | 2013-04-10 | Abbott Lab | Metodos de tratamiento con inhibidores selectivos de bcl-2 |
| RU2628560C2 (ru) | 2010-11-23 | 2017-08-18 | Эббви Инк. | Соли и кристаллические формы индуцирующего апоптоз агента |
| EP3397164B1 (en) | 2015-12-30 | 2023-05-17 | Dexcom, Inc. | System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile |
| JP6651180B2 (ja) | 2016-08-05 | 2020-02-19 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ | Ｂｃｌ−２阻害剤としてのｎ−（フェニルスルホニル）ベンズアミドおよび関連化合物 |
-
2017
- 2017-08-04 JP JP2019506191A patent/JP6651180B2/ja active Active
- 2017-08-04 EP EP19184604.7A patent/EP3569601B1/en active Active
- 2017-08-04 SM SM20210025T patent/SMT202100025T1/it unknown
- 2017-08-04 RU RU2020114660A patent/RU2744358C2/ru active
- 2017-08-04 SI SI201730535T patent/SI3494115T1/sl unknown
- 2017-08-04 CN CN201780035965.6A patent/CN109311871B/zh active Active
- 2017-08-04 KR KR1020197002744A patent/KR102376764B1/ko active Active
- 2017-08-04 DK DK17754889.8T patent/DK3494115T3/da active
- 2017-08-04 HU HUE17754889A patent/HUE053414T2/hu unknown
- 2017-08-04 RU RU2019105721A patent/RU2722560C1/ru active
- 2017-08-04 PE PE2019000335A patent/PE20190711A1/es unknown
- 2017-08-04 HR HRP20202073TT patent/HRP20202073T1/hr unknown
- 2017-08-04 SG SG10201913643YA patent/SG10201913643YA/en unknown
- 2017-08-04 CA CA3031419A patent/CA3031419C/en active Active
- 2017-08-04 EP EP22179906.7A patent/EP4129999A1/en active Pending
- 2017-08-04 KR KR1020217026744A patent/KR102429704B1/ko active Active
- 2017-08-04 ES ES17754889T patent/ES2849959T3/es active Active
- 2017-08-04 CN CN201910626474.XA patent/CN110483501B/zh active Active
- 2017-08-04 RS RS20201599A patent/RS61821B1/sr unknown
- 2017-08-04 WO PCT/US2017/045428 patent/WO2018027097A1/en not_active Ceased
- 2017-08-04 AU AU2017305508A patent/AU2017305508B2/en active Active
- 2017-08-04 SG SG11201900135YA patent/SG11201900135YA/en unknown
- 2017-08-04 EP EP17754889.8A patent/EP3494115B1/en active Active
- 2017-08-04 MX MX2019001391A patent/MX381588B/es unknown
- 2017-08-04 MY MYPI2019000239A patent/MY199409A/en unknown
- 2017-08-04 LT LTEP17754889.8T patent/LT3494115T/lt unknown
- 2017-08-04 PT PT177548898T patent/PT3494115T/pt unknown
- 2017-08-04 US US16/317,056 patent/US10829488B2/en active Active
-
2018
- 2018-08-01 US US16/051,816 patent/US10221174B2/en active Active
-
2019
- 2019-01-02 IL IL264059A patent/IL264059B/en active IP Right Grant
- 2019-01-14 ZA ZA2019/00240A patent/ZA201900240B/en unknown
- 2019-01-31 MX MX2020013014A patent/MX2020013014A/es unknown
- 2019-01-31 PH PH12019500231A patent/PH12019500231A1/en unknown
- 2019-02-04 SA SA519401020A patent/SA519401020B1/ar unknown
- 2019-07-23 JP JP2019135624A patent/JP7205903B2/ja active Active
- 2019-12-19 ZA ZA2019/08466A patent/ZA201908466B/en unknown
-
2020
- 2020-09-17 US US17/023,426 patent/US11718613B2/en active Active
-
2021
- 2021-01-15 CY CY20211100032T patent/CY1123859T1/el unknown
- 2021-04-06 AU AU2021202113A patent/AU2021202113B2/en active Active
- 2021-04-06 IL IL282099A patent/IL282099B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3031419C (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| RU2831159C2 (ru) | N-(фенилсульфонил) бензамиды и родственные соединения в качестве ингибиторов bcl-2 | |
| US20240166644A1 (en) | Sulfonyl benzamide derivatives as bcl-2 inhibitors | |
| RU2831159C9 (ru) | N-(фенилсульфонил) бензамиды и родственные соединения в качестве ингибиторов bcl-2 | |
| HK40019323A (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| HK40019323B (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| HK40001725A (en) | N-(phenylsulfonyl)benzamide derivatives as bcl-2 inhibitors | |
| HK40001725B (en) | N-(phenylsulfonyl)benzamide derivatives as bcl-2 inhibitors | |
| NZ750100B2 (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| BR112019001666B1 (pt) | Compostos de n-(fenilsulfonil)benzamidas e sais e solvatos dos mesmos, composições farmacêuticas e seus usos no tratamento de doenças, distúrbios ou afecções através da inibição de bcl-2 | |
| HK40001439B (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| HK40001439A (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190801 |